In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

HOW CELLS RESPOND TO INTERFERONS

1998 • 3,937 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

1996 • 361 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis

2003 • 205 citations

Neutralizing antibodies and efficacy of interferon β-1a

2005 • 202 citations

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1999 • 194 citations

Interferon β-1a in MS

2005 • 180 citations

Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients

2003 • 173 citations

The human intracellular Mx‐homologous protein is specifically induced by type I interferons

1990 • 161 citations

[74] Quantitation of neutralization of interferon by antibody

1986 • 127 citations

A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1b

1998 • 100 citations

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1

2005 • 94 citations

Comparative Study of the Pharmacodynamic and Pharmacologic Effects of Betaseron^®and AVONEX^™

1998 • 92 citations

Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification

2001 • 88 citations

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

2003 • 88 citations

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.

1993 • 87 citations

A comparative study of the relative bioavailability of different interferon beta preparations

2000 • 86 citations

Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS

2000 • 84 citations

Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients

2002 • 78 citations

The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies

2005 • 72 citations

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis

2004 • 72 citations

Pharmacodynamics of Biological Response In Vivo After Single and Multiple Doses of Interferon?????

1993 • 64 citations

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

2003 • 62 citations

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis

2004 • 55 citations

The immunogenicity of biopharmaceuticals

2003 • 51 citations

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

2005 • 48 citations

Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort

2005 • 44 citations

Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis

2004 • 44 citations

The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta

2001 • 35 citations

Current trials in multiple sclerosis: established evidence and future hopes

2005 • 20 citations